Merck gets FDA nod for Janumet

Share this article:
The FDA approved Merck combination pill Janumet, for type 2 diabetes. The drug contains Merck’s sitagliptin—the active ingredient in Januvia—and an older glucose-lowering agent called metformin. Januvia, part of a class of drugs called DPP-4 inhibitors, was approved in October. It enhances the body’s own ability to lower blood sugar levels. Novartis is seeking FDA approval for its own DPP-4 inhibitor, Galvus, but an FDA request for more data has delayed launch.
Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.